NO963785L - Process for the treatment of 5HT2B receptor-related conditions - Google Patents
Process for the treatment of 5HT2B receptor-related conditionsInfo
- Publication number
- NO963785L NO963785L NO963785A NO963785A NO963785L NO 963785 L NO963785 L NO 963785L NO 963785 A NO963785 A NO 963785A NO 963785 A NO963785 A NO 963785A NO 963785 L NO963785 L NO 963785L
- Authority
- NO
- Norway
- Prior art keywords
- related conditions
- treatment
- 5ht2b receptor
- receptor
- 5ht2b
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Det blir beskrevet fremgangsmåter for binding av en 5- HT2B resepter hos pattedyr ved anvendelse av både kjente og nye forbindelser. Videre blir det fremskaffet en fremgangsmåte for behandling eller forhindring av 5- HTgg relaterte tilstander. Endelig, fremskaffer foreliggende oppfinnelse en fremstilt artikkel.Methods are described for binding a 5- HT2B receptor in mammals using both known and novel compounds. Further, a method is provided for treating or preventing 5-HT 2g related conditions. Finally, the present invention provides a fabricated article.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21262294A | 1994-03-11 | 1994-03-11 | |
US08/380,566 US5688807A (en) | 1994-03-11 | 1995-02-06 | Method for treating 5HT2B receptor related conditions |
US08/380,565 US5663178A (en) | 1995-02-06 | 1995-02-06 | Tetrahydro-beta carbolines |
PCT/US1995/003099 WO1995024200A1 (en) | 1994-03-11 | 1995-03-10 | Method for treating 5ht2b receptor related conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
NO963785D0 NO963785D0 (en) | 1996-09-10 |
NO963785L true NO963785L (en) | 1996-11-01 |
Family
ID=27395770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO963785A NO963785L (en) | 1994-03-11 | 1996-09-10 | Process for the treatment of 5HT2B receptor-related conditions |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0749313A4 (en) |
JP (1) | JPH09510216A (en) |
CN (1) | CN1148340A (en) |
AU (1) | AU679635B2 (en) |
CA (1) | CA2185236A1 (en) |
CZ (1) | CZ264996A3 (en) |
FI (1) | FI963571A (en) |
HU (1) | HUT75522A (en) |
IL (1) | IL112958A0 (en) |
NO (1) | NO963785L (en) |
WO (1) | WO1995024200A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
JPH11503757A (en) * | 1995-04-18 | 1999-03-30 | イーライ・リリー・アンド・カンパニー | Use of ergoline compounds that produce physiological and pathological functions at 5-HT (7) receptors |
GB9523999D0 (en) | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
JP2000507269A (en) * | 1996-03-15 | 2000-06-13 | イーライ・リリー・アンド・カンパニー | How to treat common cold or allergic rhinitis |
US5880134A (en) * | 1996-03-20 | 1999-03-09 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor |
KR20000004966A (en) * | 1996-03-25 | 2000-01-25 | 피터 지. 스트링거 | Method for treating migraine pain |
BR9708347A (en) * | 1996-03-25 | 1999-08-03 | Lilly Co Eli | Tetrahidorbeta-carbonyl compounds |
US5886003A (en) * | 1996-03-25 | 1999-03-23 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of venomous bites and stings |
AU4856600A (en) | 1999-05-18 | 2000-12-05 | Synaptic Pharmaceutical Corporation | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder |
CN1164574C (en) | 1999-05-24 | 2004-09-01 | 三菱制药株式会社 | Phenoxypropylamine compounds |
US6444477B1 (en) * | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
GB0203412D0 (en) | 2002-02-13 | 2002-04-03 | Pharmagene Lab Ltd | 5-HT 2B receptor antagonists |
ES2313002T3 (en) * | 2003-05-09 | 2009-03-01 | Laboratorios Del Dr. Esteve, S.A. | USE OF SULFONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR PROFILAXIS AND / OR TREATMENT OF FOOD INGESTION. |
EP1852129A4 (en) * | 2005-02-08 | 2009-07-15 | Astellas Pharma Inc | Remedy for irritable bowel syndrome |
EP1923387B1 (en) | 2005-08-08 | 2011-10-19 | Astellas Pharma Inc. | Acylguanidine derivative or salt thereof |
ATE542794T1 (en) | 2006-02-20 | 2012-02-15 | Astellas Pharma Inc | PYRROLE DERIVATIVE OR SALT THEREOF |
BRPI0906244A2 (en) | 2008-03-24 | 2015-06-30 | Medivation Technologies Inc | Compound, pharmaceutical composition, method for treating a cognitive, psychotic, neurotransmitter mediated disorder or a neuronal disorder in an individual, use of a compound and kit |
BRPI0921097B8 (en) | 2008-11-21 | 2021-05-25 | Raqualia Pharma Inc | compound or its pharmaceutically acceptable salt, intermediate of the compound, pharmaceutical composition and use of the compound |
TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
CN102711467A (en) * | 2009-09-23 | 2012-10-03 | 梅迪维新技术公司 | Pyrido(3,4-b)indoles and methods of use |
US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
RU2738646C2 (en) | 2016-04-01 | 2020-12-15 | РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС | Estrogen receptor modulators |
MX2021010198A (en) * | 2019-02-27 | 2021-09-21 | Univ California | N-substituted indoles and other heterocycles for treating brain disorders. |
JP2022543832A (en) | 2019-08-06 | 2022-10-14 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Estrogen receptor modulators for treating mutants |
WO2023143393A1 (en) * | 2022-01-29 | 2023-08-03 | 上海科技大学 | Tricyclic compound, and preparation method therefor and use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492304A (en) * | 1968-06-24 | 1970-01-27 | Warner Lambert Pharmaceutical | 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones |
DE3240514A1 (en) * | 1982-10-29 | 1984-05-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | SS-CARBOLINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME |
US4520024A (en) * | 1983-02-11 | 1985-05-28 | Eli Lilly And Company | Method of selectively blocking peripheral vascular serotonergic receptors |
US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
EP0620222A3 (en) * | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
-
1995
- 1995-03-10 CZ CZ962649A patent/CZ264996A3/en unknown
- 1995-03-10 EP EP95914014A patent/EP0749313A4/en not_active Withdrawn
- 1995-03-10 HU HU9602482A patent/HUT75522A/en unknown
- 1995-03-10 CN CN95193029A patent/CN1148340A/en active Pending
- 1995-03-10 CA CA002185236A patent/CA2185236A1/en not_active Abandoned
- 1995-03-10 AU AU21186/95A patent/AU679635B2/en not_active Ceased
- 1995-03-10 IL IL11295895A patent/IL112958A0/en unknown
- 1995-03-10 WO PCT/US1995/003099 patent/WO1995024200A1/en not_active Application Discontinuation
- 1995-03-10 JP JP7523692A patent/JPH09510216A/en active Pending
-
1996
- 1996-09-10 NO NO963785A patent/NO963785L/en unknown
- 1996-09-10 FI FI963571A patent/FI963571A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP0749313A1 (en) | 1996-12-27 |
HU9602482D0 (en) | 1996-11-28 |
WO1995024200A1 (en) | 1995-09-14 |
NO963785D0 (en) | 1996-09-10 |
JPH09510216A (en) | 1997-10-14 |
EP0749313A4 (en) | 2001-10-24 |
HUT75522A (en) | 1997-05-28 |
FI963571A0 (en) | 1996-09-10 |
AU2118695A (en) | 1995-09-25 |
CA2185236A1 (en) | 1995-09-14 |
CZ264996A3 (en) | 1998-01-14 |
IL112958A0 (en) | 1995-06-29 |
FI963571A (en) | 1996-11-08 |
AU679635B2 (en) | 1997-07-03 |
CN1148340A (en) | 1997-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO963785L (en) | Process for the treatment of 5HT2B receptor-related conditions | |
DE69632293D1 (en) | Process for the production of polysiloxane-polycarbonate block copolymers | |
NO961173D0 (en) | New pyrido (3,2-e) pyrazinones with anti-asthmatic action and process for their preparation | |
DE69613770D1 (en) | Process for the production of ethylene-propylene copolymers | |
DE69701714D1 (en) | METHOD FOR TREATING GLASS SUBSTRATES | |
GB9607695D0 (en) | Process for treating oil-bearing formation | |
DE69615946T2 (en) | Process for the production of tunnel plate heat pipes | |
DE69129760T2 (en) | T-CADHERIN BINDING MOLECULE | |
DE69628912D1 (en) | PRODUCTION AND USE OF A SPECIFIC GABA-AALPHA5 RECEPTOR LIGAND FOR TREATING THE DISEASE OF ALZHEIMER | |
NO986176D0 (en) | Method of regulating Haematococcus SPP. growth process | |
DE69305323T3 (en) | Process for the production of ethylene-propylene block copolymers | |
DE59609850D1 (en) | Process for the production of vanillin and suitable microorganisms | |
NO965476L (en) | Process for surface treatment of substrate and substrate surface treated by the method | |
AU1074397A (en) | Method for treating anxiety | |
DE69626311D1 (en) | COMPOSITION FOR THE TREATMENT OF LAUNDRY AND METHOD THEREFOR | |
DE69607559T2 (en) | Process for the treatment of phenol tar | |
AU617252B2 (en) | Method of treating tinea | |
FI973173A (en) | Method for treating condensate | |
AU7726396A (en) | Method for treating anxiety | |
DK0805806T3 (en) | Process for Preparation of 4,10-diacetoxy-2alpha-benzoyloxy-5beta, 20-epoxy-1,7beta-dihydroxy-9-oxotax-11-en-13alpha | |
AU7674796A (en) | Method for treating anxiety | |
DE59600108D1 (en) | Process for the production of different sized saddle coils | |
NO960307D0 (en) | Process for the preparation of substituted 4,6-diamino-5-cyanopyrimidines | |
FI933961A (en) | Method for treating solids at high temperature | |
DE69708226T2 (en) | Process for the production of grain-oriented silicon steel sheets |